|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.10.25 - 14:06
|
Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced the appointment of Nia Tatsis, Ph.D., to its board. Dr. Tatsis is currently Executive Vice President and Chief Regulatory and Quality Officer of Vertex Pharmaceuticals and brings more than 20 years of experience in regulatory affairs and quality assurance.
“I am thrilled to welcome Nia to the board of Odyssey as we advance our RIPK2 scaffolding inhibitor and broader pipeline through clinical development,” said Gary D. Glick, Ph.D., Founder and CEO of Odyssey Therapeutics. “Nia's deep expertise spanning clinical development, regulatory, manufacturing, and commercialization will be invaluable as we continue on our mission of delivering transformative medicines to patients in need.”
Dr. Tatsis has extensive senior-level ...
|
|
|
|
|
06.10.25 - 22:03
|
Vertex to Announce Third Quarter 2025 Financial Results on November 3rd (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2025 financial results on Monday, November 3, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Third Quarter 2025 Earnings Call.”
The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website.
About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis...
|
|
|
|
|
|
|
|
|
|
|
03.10.25 - 12:42
|
Vertex Pharmaceuticals Aktie: Die Schere zwischen Nasdaq Biotech und der Aktie geht weit auseinander (Aktiencheck)
|
|
|
Paris (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von der BNP Paribas:
Egmond Haidt, Analyst der BNP Paribas, nimmt die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN: 882807, Ticker-Symbol: VX1, NASDAQ-Symbol: VRTX) unter die Lupe.
Die Schere zwischen dem Branchenindex Nasdaq Biotech Index, der hauptsächlich aus US-Unternehmen bestehe, und der Aktie von Vertex Pharmaceuticals sei weit auseinandergegangen. [mehr]...
|
|
|
|
|
|
|
|
|
26.09.25 - 08:45
|
Vertex Pharmaceuticals: Zwischen Höhenflug und Gegenwind (Sharedeals)
|
|
|
Vertex Pharmaceuticals ist seit Jahren vor allem durch seine Führungsrolle in der Behandlung von Mukoviszidose bekannt. Doch während die Forschung große Fortschritte zeigt, gerät die Aktie nach außergewöhnlich lukrativen Jahren zunehmend unter Druck – ein Spannungsfeld zwischen wissenschaftlichem Erfolg und Marktunsicherheit. Schwächung nach Allzeithoch Am 14. März 2025 erreichte die Aktie von Vertex Pharmaceuticals ihr […]
The post Vertex Pharmaceuticals: Zwischen Höhenflug und Gegenwind first appeared on sharedeals.de....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
